Menu Search
Equities

Neuren Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NK9:FRA

Neuren Pharmaceuticals Ltd

Actions
  • Price (EUR)7.45
  • Today's Change-0.40 / -5.10%
  • Shares traded680.00
  • 1 Year change+0.68%
  • Beta2.1886
Data delayed at least 15 minutes, as of Feb 16 2026 07:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

  • Revenue in AUD (TTM)228.67m
  • Net income in AUD149.06m
  • Incorporated2001
  • Employees--
  • Location
    Neuren Pharmaceuticals LtdSuite 1.01117 Camberwell Road, Hawthorn EastMELBOURNE 3123AustraliaAUS
  • Phone+61 39092-0480
  • Websitehttps://www.neurenpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.